国外平台加速器-outline
WARNING: LACTIC ACIDOSIS
Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full 免费外网加速器
If lactic acidosis is suspected, discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.
免费外网加速器
- Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis
- Prior serious hypersensitivity reaction to dapagliflozin or hypersensitivity to 推荐个能上外网的手机加速器
- Metabolic acidosis, including 手机外网免费加速器
Warnings and Precautions
Hypotension: Dapagliflozin causes intravascular volume contraction, and symptomatic hypotension can occur. Assess and correct volume status before initiating XIGDUO XR in patients with impaired renal function, elderly patients, or patients on loop diuretics. Monitor for hypotension.
Ketoacidosis has been reported in patients with type 1 and type 2 diabetes receiving dapagliflozin. Some cases were fatal. Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue XIGDUO XR, evaluate and treat promptly. Before initiating XIGDUO XR, consider risk factors for ketoacidosis. Patients on XIGDUO XR may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis.
Acute Kidney Injury: Dapagliflozin causes intravascular volume contraction and can cause acute kidney injury. Reports of acute kidney injury requiring hospitalization and dialysis have occurred with dapagliflozin. If acute kidney injury occurs, discontinue and promptly treat.
Increases in serum creatinine and decreases in eGFR may be observed with initiation of dapagliflozin. Elderly patients and patients with impaired renal function may be more susceptible to these changes. Consider temporarily discontinuing in settings of reduced oral intake or fluid losses. Before initiating XIGDUO XR, evaluate renal function and monitor periodically. XIGDUO XR is not recommended when the eGFR is <45 mL/min/1.73 m2.
Urosepsis and Pyelonephritis: SGLT2 inhibitors increase the risk for urinary tract infections (UTIs) and serious UTIs have been reported with dapagliflozin. Evaluate for signs and symptoms of UTIs and treat promptly.
Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Consider a lower dose of insulin and insulin secretagogues to reduce risk of hypoglycemia when coadministered with 免费外网加速器.
Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Rare but serious, life-threatening cases have been reported in patients receiving SGLT2 inhibitors including dapagliflozin. Cases have been reported in females and males. Serious outcomes have included hospitalization, surgeries, and death. Assess patients presenting with pain or tenderness, erythema, swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment and discontinue XIGDUO XR.
Vitamin B12 Deficiency: Metformin may lower vitamin B12 levels. Measure hematological parameters annually.
手机外网加速器 Dapagliflozin increases the risk of genital mycotic infections, particularly in patients with prior genital mycotic infections. Monitor and treat appropriately.
Adverse Reactions
Most common adverse reactions (≥5%) with dapagliflozin (5 mg or 10 mg) plus metformin vs placebo plus metformin were female genital mycotic infection (9.4%, 9.3%, 1.5%), nasopharyngitis (6.3%, 5.2%, 5.9%), urinary tract infection (6.1%, 5.5%, 3.6%), diarrhea (5.9%, 4.2%, 5.6%), and headache (5.4%, 3.3%, 2.8%), respectively.
Adverse reactions reported in >5% of patients treated with metformin XR and more commonly than in patients treated with placebo are diarrhea (9.6% vs 2.6%) and nausea/vomiting 手机外网加速器.
Use in Specific Populations
Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters. Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin may result in ovulation in some anovulatory women.
Lactation: XIGDUO XR is not recommended when breastfeeding.
INDICATION AND LIMITATIONS OF USE FOR XIGDUO XR
XIGDUO XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin is indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.
XIGDUO XR is not recommended for patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Please read US Full Prescribing Information 
, including Boxed WARNING about lactic acidosis and Medication Guide for XIGDUO XR.
